If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
58
results.
Updated on
14/10/2025 [07:12:00]
Results 50 to 58 of 58
Absstract of: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Absstract of: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Absstract of: US2025264482A1
The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.
Absstract of: US2025262247A1
The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.
Absstract of: US2025262337A1
A method for detecting soluble oligomeric amyloid β in a subject is provided.
Absstract of: CN119768689A
Use of a novel highly toxic amyloid oligomer A beta o * 3F as a target for diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), A beta o * 3F is specifically bound by a 3F antibody, and exists in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Absstract of: KR20250124673A
본 발명에 따른 치매 노인의 수면 효율을 예측하는 전자 장치는 통신부; 메모리; 상기 통신부 및 상기 메모리와 연결된 적어도 하나의 프로세서를 포함하고, 상기 적어도 하나의 프로세서는, 사용자의 활동 데이터, 수면 데이터 및 생체 데이터를 획득하고, 상기 활동 데이터, 상기 수면 데이터 및 상기 생체 데이터를 입력으로 하여 치매 노인의 수면 효율을 예측하도록 학습된 수면 효율 예측 모델에 입력 파라미터를 입력하여 각 치매 노인의 수면 효율을 출력하도록 구성되며, 상기 생체 데이터는 상기 치매 노인의 신체에 장착된 땀패치를 탈착하여 소킹(soaking)한 후 추출된 싸이토카인의 종류 및 수치 정보를 포함할 수 있다.
Nº publicación: CL2025001656A1 18/08/2025
Applicant:
WASHINGTON UNIV [US]
WASHINGTON UNIVERSITY
Absstract of: MX2023011495A
The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues and optionally Ab species to diagnose a subject, guide treatment decisions, and select subjects for clinical trials.
BOPI
Electronic site
